Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 15, 2024 2:16pm
111 Views
Post# 36041636

RE:As predicted. shorting away

RE:As predicted. shorting awayAlso, people need to realize, everything has steps of progress.
The endorcement  of GCAR, & in plain English says
" registration-enabling pathway"
Now? what about a partner to help pay for all this , or a buyout?
Stay tuned grasshopper.....
One step at a time.
Oncolytics has just announced ...up-coming trial ascoicated with a world repected Pancreatic cancer organization.
Certianly not a fraud as some meatheads have proclaimed.
No, they have additional fodder for negotiations with existing or new potential partners.
Great opportunities at that. Regrettably a few want answers last week. Want a partnership, buyout NOW....
Pointiing to lack of that , only indicates now.
last week for example, the same FUDSTERS were saying " what happned to the phase 3 panc trial..it disapeared" .
Well not gone, just imporved.
The CGAR trial by the announcment will be less costly, quicker and expected to lead directly to licensing.
Just read the N.R.

<< Previous
Bullboard Posts
Next >>